We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis (Sodermix)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01771991
Recruitment Status : Completed
First Posted : January 21, 2013
Results First Posted : April 24, 2015
Last Update Posted : February 27, 2017
Sponsor:
Information provided by (Responsible Party):
Sanford Health

Brief Summary:
The purpose of this study is to determine if topical superoxide dismutase is an effective treatment of radiation related neck fibrosis, and to determine the quality of life impact from radiation related fibrosis in the head and neck cancer patients at Sanford Health.

Condition or disease Intervention/treatment
Radiation Induced Fibrosis to the Head and Neck Drug: Topical Sodermix Dismutase in the form of Sodermix (SOD) Drug: Placebo

Detailed Description:

The primary goal of this study is to evaluate the effect of topical Superoxide Dismutase (SOD) on the radiation induced fibrosis in head and neck cancer patients. A prospective, blinded, two group control design will be used with pretest and post test quality of life as well as objective fibrosis assessment. Patients will be randomized to alternatively receive topical SOD or placebo as instructed on twice daily use for 3 months. Pre and post treatment quality of life surveys and objective assessment will determine if the topical SOD improves neck fibrosis/function and global quality of life.

This study will increase clinical trial awareness and participation while potentially improving the long term functional outcomes of head and neck cancer patients.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Topical Superoxide Dismutase For the Treatment of Radiation Induced Fibrosis in the Head and Neck Cancer Patient
Study Start Date : August 2012
Primary Completion Date : June 2013
Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Cetaphil
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Topical Sodermix Dismutase
Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to applying Topical Sodermix Dismutase in the form of Sodermix(SOD) to the area of neck skin fibrosis twice a day for 12 weeks.
Drug: Topical Sodermix Dismutase in the form of Sodermix (SOD)
Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
Other Names:
  • Sodermix
  • SOD
Placebo Comparator: Placebo group
Cetaphil cream
Drug: Placebo
Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
Other Name: Cetaphil cream



Primary Outcome Measures :
  1. Improvement in Neck Fibrosis [ Time Frame: 3 months ]
    Number of participants with improvement in fibrosis as defined as a one point improvement on the fibrosis scale using the grading scale outlined in CTCAE 4.03, page 46.


Secondary Outcome Measures :
  1. Determine the Quality of Life Impact From Radiation Related Fibrosis in Head and Neck Cancer Patients [ Time Frame: 3 months ]
    Metrics are measured via analysis of pain and range of motion and Health Related Quality of Life questionnaire.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • must have evidence of neck fibrosis
  • previous radiation treatment to the neck for cancer
  • age greater than or equal to 18 years
  • life expectancy of greater than 12 weeks
  • ability to understand the purpose of the study and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to SOD or Cetaphil cram.
  • any psychological, familial, sociological or geographical conditions that do not permit medical follow-up and compliance with the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01771991


Locations
United States, South Dakota
Sanford Health
Sioux Falls, South Dakota, United States, 57105
Sponsors and Collaborators
Sanford Health
Investigators
Principal Investigator: William C Spanos, MD Sanford Health/Sanford Clinic ENT

Responsible Party: Sanford Health
ClinicalTrials.gov Identifier: NCT01771991     History of Changes
Other Study ID Numbers: SOD 2012
First Posted: January 21, 2013    Key Record Dates
Results First Posted: April 24, 2015
Last Update Posted: February 27, 2017
Last Verified: January 2017

Keywords provided by Sanford Health:
fibrosis
radiation
neck
cancer
Sodermix

Additional relevant MeSH terms:
Fibrosis
Pathologic Processes
Superoxide Dismutase
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs